Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Breast Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Breast Cancer
    New Treatment Strategy Improves Depression in Patients With Cancer - (DGNews)
    Polygenes, risk prediction, and targeted prevention of breast cancer - (N Engl J Med)
    TopAbstracts in Breast Cancer 07/01/2008 - (DGNews)
    TopAbstracts in Breast Cancer 06/24/2008 - (DGNews)
    Obese Women in Canada Are Less Likely to Be Screened for Cervical Cancer - (DGNews)

    News archive

     Recent webcasts/CME - Breast Cancer
  • Chemotherapy Resistance in Breast Cancer: Which Mechanisms Have Clinical Relevance?
  • New Opportunities to Overcome Chemotherapy Resistance in Breast Cancer: Focus on the Epothilones
  • Targeted Therapy in Breast Cancer: Updates on Established and Novel Agents in Early Stage and Metastatic Disease
  • Breast Problems:  Common Problems in Adults (non-pregnant)

    Webcasts/CME archive

     Recent cases - Breast Cancer
      A Case of Matrix-Producing Carcinoma of the Breast
      Metastatic Hurthle Cell Carcinoma of the Thyroid Presenting as a Breast Lump: A Case Report
      Paraneoplastic Cerebellar Degeneration as a Presentation of Breast Cancer - A Case Report and Review of the Literature
      Primary Lymphoma of the Breast Involving Both Axillae with Bilateral Breast Carcinoma
      An Unusually Large Myofibroblastoma in a Male Breast: A Case Report

      Cases archive
        




      my personal edition > breast cancer > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Fewer Gynecological Problems Seen in Women on Anastrozole in ATAC Study: Presented at SABCS

      By Ed Susman

      SAN ANTONIO, TX -- December 12, 2005 -- A landmark trial comparing the efficacy of anastrozole and tamoxifen in preventing recurrence of breast cancer found that patients on the aromatase inhibitor anastrozole experienced fewer gynecological symptoms or abnormalities.

      "Considerably fewer anastrozole patients underwent diagnostic and therapeutic interventions compared with tamoxifen patients," said Sean Duffy, MD, senior lecturer and honorary consultant obstetrician and gynecologist, St. James' University Hospital, Leeds, United Kingdom.

      In the Arimidex, Tamoxifen Alone or in Combination (ATAC) Trial, anastrozole therapy reduced the risk of breast cancer recurrence better than tamoxifen. Dr. Duffy's study indicates that the use of the newer aromatase inhibitor appears to lessen gynecologic problems as well.

      In a poster presentation on December 9th at the 28th Annual San Antonio Breast Cancer Symposium (SABCS), Dr. Duffy said that the retrospective review of the patients' charts found that 1057 complained of some sort of gynecologic problem if they were on tamoxifen, compared with 634 patients taking anastrozole.

      Pain was reported by 88 patients on anastrozole and 65 patients on tamoxifen. Vaginal hemorrhage was reported by 135 patients on anastrozole and 204 patients on tamoxifen.

      Leukorrhea was reported by 85 patients and 286 patients, respectively; endometrial or uterine pathologies by 106 and 358 patients, respectively; cervical pathologies by 43 and 83 patients, respectively; infections by 336 and 375 patients, respectively; vaginal and vulval pathologies by 15 and 39 patients, respectively.

      "Gynecological adverse events and interventions cause a substantial degree of additional physical and emotional distress to patients, as well as an economic burden to the healthcare provider," Dr. Duffy noted.

      "The lower incidence of gynecological adverse events and interventions seen in patients treated with anastrozole is an important consideration for making treatment decisions regarding adjuvant endocrine therapy in postmenopausal women," he concluded.


      [Presentation title: Gynecological Interventions During Adjuvant Therapy With Anastrozole or Tamoxifen: Results From the ATAC Trial. Abstract 2056]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send